A. Dispenzieri et al., Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival, J CL ONCOL, 19(14), 2001, pp. 3350-3356
Purpose: Based on the success of hematopoietic stem-cell transplantation (H
SCT) for multiple myeloma, HSCT is being used to treat patients with primar
y systemic amyloidosis (AL). This article addresses the extent to which eli
gibility to undergo HSCT is a favorable prognostic feature and explores pro
gnostic factors within the subset of eligible patients.
patients and Methods: The Mayo Clinic amyloid database was queried for all
patients with AL seen at the Mayo Clinic from 1983 through 1997 who would h
ave been eligible for peripheral-blood stem-cell transplantation. Inclusion
criteria included biopsy-proven amyloid, symptomatic disease, absence of a
clinical diagnosis of multiple myeloma, age less than or equal to 70 years
, cardiac interventricular septal thickness less than or equal to 15 mm, ca
rdiac ejection fraction more than 55%, serum creatinine less than or equal
to 2 mg/dL, and direct bilirubin less than or equal to 2.0 mg/dL.
Results: Median age was 56 years (range, 25 to 70) with 79 (34%) older than
60 years. One hundred patients had early cardiac involvement; 41, hepatic
involvement; 167, renal involvement; and 39, nerve involvement. The 229 pat
ients have had a median follow-up of 52 months, and 151 have died. The medi
an survival was 42 months with 5- and 10-year survival rates of 36% and 15%
, respectively. Important predictors of survival were size of an-component
in 24-hour urine, number of involved organs, alkaline phosphatase, performa
nce scare, and weight loss.
Conclusion: The same patients who are eligible for HSCT are a good-risk pop
ulation who do relatively well with chemotherapy (median survival, 42 month
s), substantially better than the expected median survival of 18 months for
all patients with AL. A randomized trial is needed to assess the true effe
ct of HSCT. (C) 2001 by American Society of Clinical Oncology.